News coverage about Mesoblast (NASDAQ:MESO) has trended somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mesoblast earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8469833843859 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Global Cell Therapy Market 2018 – Dendreon, Mesoblast, Vericel, AlloCure, Amorcyte, Anterogen, Antibe Therapeutics … (factsweek.com)
- Mesoblast (MESO) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Global Cell Therapy Market Analysis 2018 Mesoblast, Dendreon, Amorcyte, AlloCure and Vericel (businessservices24.com)
- Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention? (invivo.pharmaintelligence.informa.com)
- BidaskClub Downgrades Mesoblast (MESO) to Sell (americanbankingnews.com)
MESO has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research report on Saturday, January 13th. Cantor Fitzgerald set a $20.00 target price on shares of Mesoblast and gave the company a “buy” rating in a report on Tuesday, January 16th. Maxim Group reissued a “buy” rating and issued a $14.00 price target on shares of Mesoblast in a report on Wednesday, January 31st. Finally, Credit Suisse Group lowered shares of Mesoblast from a “neutral” rating to an “underperform” rating and set a $6.00 price target for the company. in a report on Thursday, March 22nd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $13.54.
Mesoblast (NASDAQ:MESO) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $13.40 million for the quarter, compared to analyst estimates of $0.34 million. Mesoblast had a negative net margin of 188.83% and a negative return on equity of 9.78%. sell-side analysts expect that Mesoblast will post -0.49 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Mesoblast (NASDAQ:MESO) Stock Price” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/22/mesoblast-meso-getting-somewhat-positive-news-coverage-analysis-shows.html.
Mesoblast Company Profile
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.